Abstract:A modularized DNA nanodevice agonist (DNDA) has been rationally designed and constructed as both a nanocarrier and agonist. DNA‐based modules with desired functions enable DNDA to accomplish macrophage‐selective uptake and programmable cGAS‐STING activation. By reversing the immunosuppressive tumor microenvironment, DNDA exhibits a synergistic therapeutic effect when combined with immune checkpoint inhibitors. The cell‐selective STING activation with biocompatibility makes it potential for clinical translation. The activation of cyclic GMP‐AMP (cGAMP) synthase (cGAS) and its adaptor, stimulator of interferon genes (STING), is known to reprogram the immunosuppressive tumor microenvironment for promoting antitumor immunity. To enhance the efficiency of cGAS‐STING pathway activation, macrophage‐selective uptake, and programmable cytosolic release are crucial for the delivery of STING agonists. However, existing polymer‐ or lipid‐based delivery systems encounter difficulty in integrating multiple functions meanwhile maintaining precise control and simple procedures. Herein, inspired by cGAS being a natural DNA sensor, a modularized DNA nanodevice agonist (DNDA) is designed that enable macrophage‐selective uptake and programmable activation of the cGAS‐STING pathway through precise self‐assembly. The resulting DNA nanodevice acts as both a nanocarrier and agonist. Upon local administration, it demonstrates the ability of macrophage‐selective uptake, endosomal escape, and cytosolic release of the cGAS‐recognizing DNA segment, leading to robust activation of the cGAS‐STING pathway and enhanced antitumor efficacy. Moreover, DNDA elicits a synergistic therapeutic effect when combined with immune checkpoint blockade. The study broadens the application of DNA nanotechnology as an immune stimulator for cGAS‐STING activation.

MicroRNA‐Responsive DNA Dendrimer Acts As a Smart STING Signal Amplifier

A DNA‐Modularized STING Agonist with Macrophage‐Selectivity and Programmability for Enhanced Anti‐Tumor Immunotherapy

Cell-to-cell communications of cGAS-STING pathway in tumor immune microenvironment.

A DNA‐Modularized STING Agonist with Macrophage‐Selectivity and Programmability for Enhanced Anti‐Tumor Immunotherapy (Adv. Sci. 32/2024)

pH‐Responsive STING‐Activating DNA Nanovaccines for Cancer Immunotherapy

Tumor-associated miRNAs activated HCR-DNAzyme theranostic nanosystem to trigger innate- and adaptive-immune responses for long-term immunotherapy

Supramolecular Cyclic Dinucleotide Nanoparticles for STING-Mediated Cancer Immunotherapy

Nano-STING agonist-decorated microrobots boost innate and adaptive anti-tumor immunity

Virus-Like Particle-Induced cGAS-STING Activation and AIM2 Inflammasome-Mediated Pyroptosis for Robust Cancer Immunotherapy.

cGAS-STING pathway in cancer biotherapy

Synergistic immunostimulation for tumor sensitization with a biomineralized DNA sponge

Cancer Immunotherapy Based on Cell Membrane-Coated Nanocomposites Augmenting Cgas/sting Activation by Efferocytosis Blockade

Design and syntheses of a bimolecular STING agonist based on the covalent STING antagonist

GAS-STING: a classical DNA recognition pathways to tumor therapy

Amplifying STING activation by cyclic dinucleotide–manganese particles for local and systemic cancer metalloimmunotherapy

cGAS-STING pathway mediates activation of dendritic cell sensing of immunogenic tumors

STING-mediated DNA sensing in cancer immunotherapy

Strategies involving STING pathway activation for cancer immunotherapy: mechanism and agonists

The cGAS/STING Pathway: A Novel Target for Cancer Therapy

Engineering the Immune Adaptor Protein STING as a Biologic

Tumor-responsive Covalent Organic Polymeric Nanoparticles Enhancing STING Activation for Cancer Immunotherapy